Melane Sampson, Author at BioTuesdays

Developments

MIEC grants Aethlon full ethics approval for Hemopurifier cancer trial in India

Aethlon Medical (NASDAQ:AEMD), has announced that the Medanta Institutional Ethics Committee (MIEC) has granted full ethics approval for a safety, feasibility, and dose finding study of its Hemopurifier in cancer...

September 19, 2024

Developments

Senseonics and Ascensia receive FDA approval for world’s first CGM with 365-day sensor

Senseonics Holdings (NYSE:SENS) and closely-held Ascensia Diabetes Care herald a significant breakthrough in diabetes technology and management, announcing FDA approval of Eversense 365, the world’s first one-year...

September 18, 2024

Developments

PharmaJet and Scancell forge alliance to develop and commercialize needle-free DNA vaccine for advanced melanoma

Closely-held PharmaJet has announced a strategic partnership with Scancell Holdings (AIM:SCLP) to supply its Stratis Intramuscular (IM) Needle-free Injection System for delivery of Scancell’s advanced melanoma DNA...

September 17, 2024

Developments

Ripple and AbbVie launch strategic partnership to leverage eye care expertise and drug delivery innovation for next-gen glaucoma therapies

Closely-held Ripple Therapeutics has entered into a collaboration and option-to-lease agreement with AbbeVie (NYSE:ABBV) to develop RTC-620, a next generation, fully biodegradable, sustained-release drug delivery...

September 17, 2024

Feature

InfoBionic.Ai innovating a beat ahead with gold standard remote cardiac care

Closely-held InfoBionic.Ai, a pioneering virtual cardiac telemetry company, is transforming cardiac patient care by equipping healthcare providers with a sophisticated ecosystem of solutions designed to enhance every...

September 17, 2024

Developments

Profound’s PRO-Talk Live! 2024 spotlights the future of prostate disease care with TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) hosted its second PRO-Talk Live! educational event, by physicians for physicians, in Las Vegas this past weekend. The event featured a prestigious panel of experts, innovators...

September 16, 2024

Developments

Evaxion reports positive one-year Phase 2 data on personalized cancer vaccine

Evaxion Biotech (NASDAQ:EVAX) has announced positive one-year data from its Phase 2 trial of the AI-designed personalized cancer vaccine, EVX-01, a potential treatment for melanoma. The data, from a one-year interim...

September 16, 2024

Developments

Cidara’s workforce restructuring enables focus on clinical development

Cidara Therapeutics (NASDAQ:CDTX) has announced a planned workforce reduction, impacting approximately 30% of the company’s employees, enabling the company to reduce capital needs and concentrate on the clinical...

September 13, 2024

Developments

Tenon prepares to launch new joint fixation device with 30% reduction in implant width

Tenon Medical (NASDAQ:TNON) announced the limited alpha launch of its new Catamaran SE SI Joint Fusion System in early Q4. The company aims to gather initial user feedback from a select group of physicians to support a...

September 13, 2024

Developments

Aura announces positive Phase 2 EOS results evaluating bel-sar for CM

Aura Biosciences (NASDAQ:AURA) has announced positive Phase 2 end-of-study (EOS) results evaluating the safety, tolerability, and efficacy of bel-sar (AU-011) for the first-line treatment of early-stage choroidal...

September 12, 2024

Author - Melane Sampson

MIEC grants Aethlon full ethics approval for Hemopurifier cancer trial in India

Senseonics and Ascensia receive FDA approval for world’s first CGM with 365-day sensor

PharmaJet and Scancell forge alliance to develop and commercialize needle-free DNA vaccine for advanced melanoma

Ripple and AbbVie launch strategic partnership to leverage eye care expertise and drug delivery innovation for next-gen glaucoma therapies

InfoBionic.Ai innovating a beat ahead with gold standard remote cardiac care

Profound’s PRO-Talk Live! 2024 spotlights the future of prostate disease care with TULSA-PRO

Evaxion reports positive one-year Phase 2 data on personalized cancer vaccine

Cidara’s workforce restructuring enables focus on clinical development

Tenon prepares to launch new joint fixation device with 30% reduction in implant width

Aura announces positive Phase 2 EOS results evaluating bel-sar for CM

General

More